ALAN is a partner of MRD Testing Collaborative – a group dedicated to providing education on minimal residual disease testing in the blood cancer community
The mission and purpose of the MRD Testing Collaborative is to inform patients and health care professionals on personalized testing in the blood cancer community, with a focus on minimal residual disease (MRD). The Collaborative also brings together like-minded patient advocacy stakeholders and industry partners to collectively address blood cancer patient needs regarding testing.
Minimal Residual Disease (MRD) is the name for the small amount of cancer cells in a patient’s body following treatment. Most commonly, MRD tests are used to develop and guide treatment plans for leukemia, myeloma, and lymphoma and the tests to find MRD can vary based on the type of blood cancer an individual has. This Resource Center is intended to provide helpful materials and information on MRD testing to support blood cancer patients and their families.
For more information and resource center: www.bemrdaware.com